Evgen Pharma ( (GB:TCF) ) just unveiled an announcement.
TheraCryf plc has signed a Master Service Agreement with Pharmaron UK Ltd to advance the development of its Orexin-1 addiction programme. This agreement will enable the completion of preclinical data packages necessary for clinical trial authorization, with work expected to begin imminently and full completion anticipated by the second half of 2026. The collaboration with Pharmaron is a strategic move following TheraCryf’s recent £4.25 million fundraise, positioning the company to efficiently progress towards human clinical trials and potentially address addictive and impulsive conditions, thereby strengthening its market position in neuropsychiatry and oncology.
Spark’s Take on GB:TCF Stock
According to Spark, TipRanks’ AI Analyst, GB:TCF is a Neutral.
Evgen Pharma’s overall stock score of 49 reflects ongoing financial and operational challenges, including declining revenues and losses. While the technical analysis shows mixed momentum, recent corporate events provide a positive outlook with strategic initiatives aimed at improving financial stability and advancing key drug development programs.
To see Spark’s full report on GB:TCF stock, click here.
More about Evgen Pharma
TheraCryf plc is a clinical stage drug development company focusing on brain disorders, with a broad pipeline in areas such as addiction, anxiety, fatigue, narcolepsy, glioblastoma, and neurodevelopmental disorders. The company aims to generate compelling data sets to preclinical and clinical proof of concept and partners with mid-size to large pharmaceutical companies for larger trials and commercialization. TheraCryf collaborates with major universities and hospitals and is headquartered in Alderley Park, Cheshire, trading on AIM in London under the ticker symbol TCF.
Average Trading Volume: 4,304,682
Technical Sentiment Signal: Sell
Current Market Cap: £5.05M
See more data about TCF stock on TipRanks’ Stock Analysis page.